Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
Phase 1
Recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT05985954
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
Phase 2
Recruiting
- Conditions
- CarcinomatosisGastric Adenocarcinoma
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05977998
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
Phase 2
Recruiting
- Conditions
- Cholangiocarcinoma
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05967182
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Phase 1
Withdrawn
- Conditions
- Refractory B-cell Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05961696
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT05961709
- Locations
- 🇺🇸
Baptist - MD Anderson Cancer Center, Jacksonville, Florida, United States
🇺🇸Ochsner, New Orleans, Louisiana, United States
🇺🇸Cooper University Medical Center, Camden, New Jersey, United States
Data Collection Protocol for Patients With Von Hippel Lindau Disease
Recruiting
- Conditions
- Von Hippel Lindau Disease
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 125
- Registration Number
- NCT05955014
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Reminder Messages for Lung Cancer Screening
Recruiting
- Conditions
- Skin FlapsLung Cancer
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 130
- Registration Number
- NCT05952778
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal Adenocarcinoma
Not Applicable
Recruiting
- Conditions
- Appendiceal AdenocarcinomaColorectal
- Interventions
- Procedure: Circulating tumoral DNA directed neoadjuvant therapy arm
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT05947838
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Pilot Clinical Trial to Determine the Feasibility of Administering an Electronic Tool to Assess Postoperative pAin, Nausea, and Vomiting in English or Spanish-Speaking Pediatric Patients With Neoplastic Conditions.
Not Applicable
Completed
- Conditions
- Neoplastic Conditions
- Interventions
- Other: Augmented reality (AR)
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT05933252
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
Phase 2
Withdrawn
- Conditions
- Large B-cell LymphomaB-cell Lymphoma
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05929716
© Copyright 2025. All Rights Reserved by MedPath